Abstract : Femoston® Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston® Low is in agreement with the recent recommendations for menopausal hormone replacement therapy, which give the preference to low dosage therapy when-ever possible. The goals are to potentially minimize the risk of breast cancer, the danger of venous or arterial thrombosis and the glucose and lipid metabolic disturbances. Nevertheless, the preparation should efficaciously oppose to endometrial hyperplasia and yield a high degree of amenorrhea. KEYWORDS : Dydrogesterone - Estradiol - Menopause - Hormone replacement therapy